Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HRS-8080 versus physician's choice therapy in endocrine-pretreated advanced or metastatic breast cancer
CTR20252296Phase 3Active
- Sponsor
- Shandong Sende
- Start
- Jul 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-8080 in breast cancer, sponsored by Shandong Sende. Started Jul 2025; status: active.
02
Drugs
HRS-8080
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20252296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252296.